Patients
| . | Total . | ≥ 65 y . | < 65 y . | P . |
|---|---|---|---|---|
| Patients, n (%) | 559 | 115 (21) | 444 (79) | |
| Males, n (%) | 336 (60) | 71 (61) | 265 (59) | .75 |
| Age, y* | 52 (18-84) | 71 (65-84) | 46 (18-64) | |
| Prior HU* | 254 (45) | 48 (42) | 206 (46) | .4 |
| Hemoglobin, g/dL* | 12.2 (6.4-17.5) | 12.8 (7.5-16.3) | 12.1 (6.4-17.5) | .02 |
| White blood cells, ×109/L* | 54.8 (1-500) | 42 (4-481) | 61 (1-500) | .01 |
| Blast cells, %* | 1 (0-10) | 0 (0-8) | 1 (0-10) | < .0001 |
| Eosinophils, %* | 2 (0-15) | 2 (0-11) | 2 (0-15) | .53 |
| Basophils, %* | 1 (0-19) | 2 (0-16) | 2 (0-19) | .47 |
| Platelets, ×109/L* | 352 (74-4920) | 337 (74-1520) | 355 (90-4920) | .11 |
| Spleen, cm below costal margin* | 2 (0-24) | 0 (0-15) | 2 (0-24) | < .0001 |
| Sokal, n (%) | ||||
| Low | 219 (39) | 10 (9) | 209 (47) | < .0001 |
| Intermediate | 216 (39) | 83 (72) | 133 (30) | |
| High | 124 (22) | 22 (19) | 102 (23) | |
| ECOG performance status, n (%) | ||||
| 0 | 0 | 0 | 0 | .37 |
| 1 | 441(79) | 87 (76) | 354 (80) | |
| 2 | 118 (21) | 28 (24) | 90 (20) | |
| High-dose imatinib, n (%) | 136 (24) | 26 (23) | 110 (25) | .71 |
| . | Total . | ≥ 65 y . | < 65 y . | P . |
|---|---|---|---|---|
| Patients, n (%) | 559 | 115 (21) | 444 (79) | |
| Males, n (%) | 336 (60) | 71 (61) | 265 (59) | .75 |
| Age, y* | 52 (18-84) | 71 (65-84) | 46 (18-64) | |
| Prior HU* | 254 (45) | 48 (42) | 206 (46) | .4 |
| Hemoglobin, g/dL* | 12.2 (6.4-17.5) | 12.8 (7.5-16.3) | 12.1 (6.4-17.5) | .02 |
| White blood cells, ×109/L* | 54.8 (1-500) | 42 (4-481) | 61 (1-500) | .01 |
| Blast cells, %* | 1 (0-10) | 0 (0-8) | 1 (0-10) | < .0001 |
| Eosinophils, %* | 2 (0-15) | 2 (0-11) | 2 (0-15) | .53 |
| Basophils, %* | 1 (0-19) | 2 (0-16) | 2 (0-19) | .47 |
| Platelets, ×109/L* | 352 (74-4920) | 337 (74-1520) | 355 (90-4920) | .11 |
| Spleen, cm below costal margin* | 2 (0-24) | 0 (0-15) | 2 (0-24) | < .0001 |
| Sokal, n (%) | ||||
| Low | 219 (39) | 10 (9) | 209 (47) | < .0001 |
| Intermediate | 216 (39) | 83 (72) | 133 (30) | |
| High | 124 (22) | 22 (19) | 102 (23) | |
| ECOG performance status, n (%) | ||||
| 0 | 0 | 0 | 0 | .37 |
| 1 | 441(79) | 87 (76) | 354 (80) | |
| 2 | 118 (21) | 28 (24) | 90 (20) | |
| High-dose imatinib, n (%) | 136 (24) | 26 (23) | 110 (25) | .71 |
No relevant baseline differences were evident between the 2 groups of patients, apart from the risk distribution: a larger proportion of younger patients were low Sokal risk versus older ones; high Sokal risk was equally represented in the 2 cohorts.
HU indicates hydroxyurea; and ECOG, Eastern Cooperative Oncology Group.
Median (range).